Table 6:

Areas for further clinical research in the field of ARVD

• RCTs enrolling patients with haemodynamically significant ARVD and high-risk clinical presentations, with true renovascular hypertension rather than patients with primary hypertension and incidental RAS through a wider and more systematic use of the translesional pressure gradient• Studies testing the impact of functional non-invasive imaging, such as BOLD MRI, to identify patients more likely to benefit from revascularization• Studies examining the efficacy of PTRA on moderate versus advanced CKD• Studies establishing the optimal timeline of revascularization to avoid delay-related ineffectiveness• Studies identifying predictors of PTRA benefit• Studies evaluating the efficacy of PTRA in combination with novel therapeutic strategies (e.g. targeting inflammation-related pathways, mesenchymal stem cells or angiogenic/growth factors)